CVS, Walgreens and Walmart Settle Opioid Lawsuits for $13B

November 3, 2022 by Tom Ramstack
CVS, Walgreens and Walmart Settle Opioid Lawsuits for $13B
CVS Pharmacy (Photo by Dan McCue)

Drugstore retailers CVS Pharmacy and Walgreens on Wednesday announced a $10 billion settlement of thousands of state and local lawsuits accusing the companies of mishandling their sales of opioid painkillers.

Walmart has tentatively agreed to pay another $3 billion to settle claims.

The agreements could end years of lawsuits if they win final approval from states, cities and counties that sued on behalf of their citizens.

Opioids are powerful painkillers known for giving users a sense of euphoria that can be addictive. They are blamed for more than 500,000 deaths in the United States in the past two decades.

Beginning with an aggressive pharmaceutical company marketing campaign that downplayed dangers of the drug, opioid prescriptions rose in the United States from 76 million in 1991 to 207 million in 2013, when the Food and Drug Administration realized their use was getting out of control.

By 2014, nearly two million Americans abused or were dependent on prescription opioids, according to the Centers for Disease Control and Prevention.

The CDC’s National Center for Health Statistics reported that 71,238 Americans died from opioids last year, up from 57,834 in 2020.

Persons who became addicted to the drugs, or families of the deceased victims, sued pharmaceutical companies that manufactured them and their distributors, such as CVS, Walgreens and Walmart.

The manufacturers have already settled for $26 billion. They included Johnson & Johnson, AmerisourceBergen Corp., Cardinal Health Inc. and McKesson Corp.

The retailers said doctors who prescribed the drugs should be blamed, not the drugstores. Their legal defense met with different degrees of success or failure in various states.

The lawsuits accused the companies of filling vast numbers of opioid prescriptions that were not medically necessary.

The lawsuits were consolidated into class actions that were being handled primarily by federal courts in Ohio and San Francisco. Settlement discussions with state attorneys general started shortly after the companies lost key legal battles in both courts.

The settlement money is supposed to be used to control drug addictions in states and cities that will share the money.

“We are pleased to resolve these longstanding claims and putting them behind us is in the best interest of all parties, as well as our customers, colleagues and shareholders,” Thomas Moriarty, CVS chief policy officer and general counsel, said in a statement.

Walgreens said in a statement: “As one of the largest pharmacy chains in the nation, we remain committed to being a part of the solution, and this settlement framework will allow us to keep our focus on the health and wellbeing of our customers and patients, while making positive contributions to address the opioid crisis.”

A statement from lawyers for local governments said, “These agreements will be the first resolutions reached with pharmacy chains and will equip communities across the country with the much-needed tools to fight back against this epidemic and bring about tangible, positive change.”

Tom can be reached at [email protected] or on Twitter at @tramstack.

A+
a-
  • CVS
  • lawsuits
  • Opioids
  • Walgreens
  • Walmart
  • In The News

    Health

    Voting

    Prescription Drugs

    What Do Weight Loss Drugs Mean for a Diet Industry Built on Eating Less and Exercising More?

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds... Read More

    NEW YORK (AP) — Ever since college, Brad Jobling struggled with his weight, fluctuating between a low of 155 pounds when he was in his 30s to as high as 220. He spent a decade tracking calories on WeightWatchers, but the pounds he dropped always crept... Read More

    April 24, 2024
    by Dan McCue
    FDA Approves New Treatment for Urinary Tract Infections

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary... Read More

    WASHINGTON — The Food and Drug Administration approved Pivya (pivmecillinam) tablets for the treatment of female adults with uncomplicated urinary tract infections.  “Uncomplicated UTIs are a very common condition impacting women and one of the most frequent reasons for antibiotic use,” said Dr. Peter Kim, M.S.,... Read More

    April 23, 2024
    by Beth McCue
    Study Finds Next-Gen Antibiotics Underutilized

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat... Read More

    WASHINGTON — A new study conducted by researchers at the National Institutes of Health found clinicians frequently continue to treat antibiotic-resistant infections with older generic antibiotics considered to be less effective and less safe than newer ones. Researchers examined the factors influencing doctors’ preference for older... Read More

    April 17, 2024
    by Dan McCue
    Eli Lilly Obesity Drug Appears to Ease Sleep Apnea Symptoms in Trials

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its... Read More

    WASHINGTON — A pair of yearlong clinical trials conducted by the drug maker Eli Lilly appear to show that its obesity drug, Zepbound, can provide considerable relief to overweight people who have sleep apnea. Though the findings have yet to be published in a peer-reviewed medical... Read More

    Many Cancer Drugs Remain Unproven Five Years After Accelerated Approval, a Study Finds

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often... Read More

    The U.S. Food and Drug Administration’s accelerated approval program is meant to give patients early access to promising drugs. But how often do these drugs actually improve or extend patients’ lives? In a new study, researchers found that most cancer drugs granted accelerated approval do not demonstrate such... Read More

    ALS Drug Will Be Pulled From US Market After Study Showed Patients Didn't Benefit

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it... Read More

    WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and... Read More

    News From The Well
    scroll top